

REC No	Recruitment Close Date	Research Title	Local Target	Active Status	
06/MRE01/102	31/03/2010	A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-III A Non small Cell Lung Carcinoma who have	10	Closed - follow up complete	N
08/H0502/132	14/10/2011	BH21260- A randomised, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment wit	9	Closed - follow up complete	Y
09/H0706/22	14/12/2013	Aliskiren vs enalapril in chronic heart failure	4	Closed - follow up complete	Y
09/H0802/125	27/01/2017	An OpenLabel, MultiCenter, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalised Adult, Adolescent and Paediatric Subjects with Confirmed Influenza Infection	1	Closed - follow up complete	N
12/SC/0527	26/02/2014	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis	2	Closed - follow up complete	N
07/MRE08/40	31/05/2012	A double-blind randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen -Specific Cancer immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3 - postive Non -Small Cell Lung Cancer	12	Closed - in follow up	N
09/H0605/87	31/05/2012	TECOS - A Randomised, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycaemic Control on Mono or Dual Combination Oral Antihyperglycaemic The	35	Closed - in follow up	Y

09/H0406/110	11/10/2012	A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction (CLCZ696B2	6	Closed - in follow up	Y
09/H0402/101	31/01/2011	A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus (The CANVAS Trial: CANagliflozin CardioVascular Assessment Study)	8	Closed - in follow up	Y
09/H0206/40	30/03/2011	A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a selected population with Low HER2-expressing Locally Recurr	10	Closed - in follow up	N
10/H0405/23	31/05/2011	A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent	22	Closed - in follow up	Y
09/H0405/44	10/10/2011	A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.	10	Closed - in follow up	N
10/H0808/109	30/04/2014	Evaluation of XIENCE PRIME™ or XIENCE V® versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.	25	Closed - in follow up	Y

11/YH/0121	11/01/2013	A phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma	2	Closed - in follow up	Y
11/NW/0298	17/01/2014	A multicenter, Phase III, open-label, randomized study in previously untreated patients with advanced indolent non-Hodgkin's Lymphoma comparing GA101 (Ro5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab maintenance	5	Closed - in follow up	Y
11/NW/0472	27/11/2013	Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, late stage (IIIb/IV) NSCLC patients eligible to receive standard treatment and supportive care.	6	Closed - in follow up	Y
11/AL/0327	25/05/2012	A Phase 2, Multicentre, randomised, double-blind, placebo controlled study of the safety, clinical activity and pharmacokinetics of Bosutinib (PF-05208763) versus placebo in subjects with autosomal dominant polycystic kidney disease (ADPKD)	5	Closed - in follow up	N
11/EM/0270	14/05/2012	A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults with Uncontrolled, Severe Asthma	4	Closed - in follow up	N
11/LO/0548	10/08/2012	An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor Therapies)	3	Closed - in follow up	N

11/LO/1728	15/02/2013	Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years. A randomised, double-blind, multicentre, placebo controlled, pha	5	Closed - in follow up	N
11/EM/0180	13/03/2013	A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis (RA)	6	Closed - in follow up	N
11/WA/0309	27/11/2012	A Comparison of LY2605541 versus Insulin Glargine as Basal Insulin Treatment in Combination with Oral AntiHyperglycemia Medications in Insulin Naive Patients with Type 2 Diabetes Mellitus: A DoubleBlind, Randomized Study: The IMAGINE 2 Study.	6	Closed - in follow up	N
11/LO/1408	04/06/2013	ABSORB II RANDOMIZED CONTROLLED TRIAL: A clinical evaluation to compare the safety, efficacy and performance of ABSORB TM everolimus eluting bioresorbable vascular scaffold system against XIENCE PRIME TM everolimus eluting coronary stent system in the tre	10	Closed - in follow up	Y
12/EE/0005	30/06/2014	A multicentre, double blind, randomised controlled Clinical Investigation to validate the EPS1 device as a treatment for stroke induced dysphagia. A Study of Swallowing Treatment using Electrical Pharyngeal Stimulation (STEPS Study)	3	Closed - in follow up	Y
11/EE/0291	26/09/2012	A Phase 3, Randomised, Open Label Trial of Lenalidomide/ dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma	7	Closed - in follow up	N

11/NE/0124	09/08/2013	A Phase III, Randomized, Comparative, Openlabel Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison with Intravenous Iron Sucrose in Subjects with Stage 5 Chronic	10	Closed - in follow up	Y
12/SC/0035	31/08/2015	A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 paediatric subjects 4-11 years old with persistent asthma.	6	Closed - in follow up	N
12/EM/0018	28/01/2014	A randomised, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.	10	Closed - in follow up	N
11/LO/0608	14/06/2013	A Randomized, Double Blind, Phase II Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer	4	Closed - in follow up	N
12/WS/0230	20/12/2013	NEFIGAN Trial: A Multicentre, Interventional treatment, Randomized, Double-Blind, Single Group Assignment Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in primary IgA nephropathy patients at risk of develo	4	Closed - in follow up	Y
12/EM/0284	25/03/2013	A multi-centre, open-label, long term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial	5	Closed - in follow up	Y
12/LO/1285	30/09/2013	A prospective, randomized, open label, parallel group, active controlled, multicenter study exploring the efficacy and safety of once daily oral rivaroxaban (BAY 597939) compared with that of dose adjusted oral vitamin K antagonists (VKA) for the preventi	13	Closed - in follow up	Y

12/EM/0308	28/02/2013	A multicenter, double-blind and open label, 2 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis treated with eith	2	Closed - in follow up	Y
12/NE/0314	28/02/2013	Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children with Haemophilia B	1	Closed - in follow up	Y
12/LO/1590	23/03/2013	A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those i	1	Closed - in follow up	N
11/EE/0311	31/03/2014	A randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent nonHodgkin's lymphoma who completed and responded to rituximabbased immunochem	5	Closed - in follow up	Y
12/EM/0349	11/06/2014	A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment	3	Closed - in follow up	Y
12/EM/0395	27/02/2014	A randomised, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Diseas	30	Closed - in follow up	Y

12/SC/0435	31/07/2014	Efficacy and safety of 3 doses of S38093 (2, 5 and 20mg/day) versus placebo in coadministration with donepezil (10mg/day) in patients with moderate Alzheimer's Disease. A 24 week international, multicentre, randomised, doubleblind, placebocontrolled phase	10	Closed - in follow up	N
13/NE/0001	07/02/2014	NN7088-3885 (Pathfinder 5): A multinational, open-label, non-controlled trial on safety, efficacy and pharmacokinetics of NNC 0129-0000-1003 in previously treated paediatric patients with severe haemophilia A	1	Closed - in follow up	Y
13/YH/0003	31/08/2013	An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma with 17p Deletion	1	Closed - in follow up	Y
12HAEM15	22/11/2013	Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes	5	Closed - in follow up	N
13/EM/0097	11/12/2013	MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials	8	Closed - in follow up	N
12/LO/1697	25/10/2013	BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy	1	Closed - in follow up	N
13/EM/0084	31/10/2013	A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A	1	Closed - in follow up	Y

13/SC/0010	10/04/2014	A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY 85-8501 in Patients with non-Cystic Fibrosis Bronchiectasis	3	Closed - in follow up	Y
11/SC/0438	31/07/2014	REPLACE (Randomised evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomised, double-blind, placebo-controlled, phase III study for the use of Fibrinogen Concentrate (Human) (FCH) in	7	Closed - in follow up	N
13/NI/0044	28/02/2014	A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID DEPENDENT ASTHMA	6	Closed - in follow up	N
13/NE/0080	02/06/2014	A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three times daily in patients with Type 2 diabetes insufficien	3	Closed - in follow up	N
13/LO/0033	01/07/2014	A Phase II, randomized study of paclitaxel with GDC-0941 versus paclitaxel with placebo in patients with locally recurrent or metastatic breast cancer	2	Closed - in follow up	Y
13/EE/0247	13/06/2014	A Phase 2a, 4-Week Treatment Period, Randomized, Double-Blind, Parallel Group, PA Phase 2a, 4-Week Treatment Period, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of Inhal	6	Closed - in follow up	Y
13/EM/0414	31/07/2014	A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy.	3	Closed - in follow up	Y

13/LO/0578	18/06/2014	A randomized, double blind, placebo controlled, multi-centre study to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in chronic obstructive pulmonary disease patients with cachexia	3	Closed - in follow up	N
14/SC/0104	31/10/2014	A Phase 2b, Randomized, Double blind, Placebo-controlled, Parallel group, Multicentre, Dose finding Study to evaluate the Efficiency, Safety and Tolerability of AZD1722 to Treat Hyperphosphataemia in End-Stage Renal Disease on Haemodialysis(ESRD-HD)	5	Closed - in follow up	Y
14/EE/0076	07/11/2014	A Phase 4, Randomized, Double-Blind Study with a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects with Relapsing-Remitting Multiple Sclerosis (MS) Treated with Tecfidera™ (dimethyl fumarate) delayed-release capsules	6	Closed - in follow up	Y
14/NW/0017	07/11/2014	A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients	7	Closed - in follow up	N
10/MREC00/61	01/08/2014	An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + RO5072759 (GA101) in patients with Rituximab-refractory, indolent Non-Hodgkin's Lymphoma)	6	Open	N/A
11/LO/0954	01/05/2017	LUXHead & Neck 2; A randomised, doubleblind, placebo controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients with stage III, IVa, or IVb locoregiona	5	Open	N/A

11/SS/0054	31/12/2014	Clinical Trial of the SonRtip Lead and Automatic AVV Optimization Algorithm in the Paradym RF SonR CRT-D (RESPOND CRT)	10	Open	N/A
12/LO/0098	28/02/2014	CAIN457 to assess safety tolerability efficacy & PK in asthma	5	Open	N/A
12/WM/0039	31/12/2014	INOVATEHF: INcrease Of VAgal TonE in chronic Heart Failure.	10	Open	N/A
12/SC/0434	31/12/2014	A randomised, multicentre, double blind, placebo controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to seventeen years	4	Open	N/A
13/NW/0003	01/03/2015	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE-3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF ART-123 IN SUBJECTS WITH SEVERE SEPSIS AND COAGULOPATHY	6	Open	N/A
12/LO/1125	31/12/2014	Occlutech percutaneous PFO closure:Safety and Efficacy OPPOSE Registry	15	Open	N/A
13/ES/0005	15/06/2015	A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia	4	Open	N/A
13/SC/0092	29/05/2014	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of siponimod (BAF312) in patients with secondary progressive multiple sclerosis	6	Open	N/A
13/SC/0102	16/12/2014	A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer	3	Open	N/A

13/SC/0073	31/08/2013	A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and Left Ventricular Systolic Dysfunction	6	Open	N/A
12/LO/1825	01/01/2015	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma	2	Open	N/A
13/LO/0105	01/02/2015	Open-label, single-arm, phase IV, multicentre trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with growth hormone deficiency (GHD) of adult onset	4	Open	N/A
13/WA/0084	06/10/2014	A Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus	7	Open	N/A
13/LO/0418	31/03/2014	A multi-centre, randomised, placebo controlled double blind, two armed, parallel group study to evaluate efficacy and safety of IV Sildenafil in the treatment of neonates persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failu	3	Open	N/A
13/LO/0326	02/03/2015	A Randomized, Phase 3 Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small-Cell Lung Adenocarcinoma	8	Open	N/A

13/WM/0114	30/10/2014	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma	5	Open	N/A
13/LO/0021	31/01/2015	Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)	6	Open	N/A
13/YH/0140	15/06/2015	Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with Chronic Heart Failure with Preserved left ventricular Ejection Fraction An 8-month, randomised double-blind, placebo controlled, int	6	Open	N/A
13/EM/0251	21/12/2015	A multicenter, randomized, double-blind, placebo- controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients	6	Open	N/A
13/EM/0230	01/08/2015	A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS 6063 in Subjects with Malignant Pleural Mesothelioma	10	Open	N/A
13/EM/0149	12/02/2015	Multicenter open-label study to evaluate efficacy of gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) for detection of significant coronary artery disease (CAD) in subjects with known or suspected CAD by a blinded image analysis	15	Open	N/A
13/NW/0006	31/03/2015	A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas	3	Open	N/A
12/LO/1950	28/11/2014	A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma	8	Open	N/A

13/LO/0219	01/12/2016	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER)	5	Open	N/A
13/LO/0491	30/11/2014	A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antagonist, in Patients with Large Reperfused ST-Elevation Myocardial Infarction	5	Open	N/A
13/LO/0704	15/12/2014	A dose ranging study investigating the efficacy and safety of sublingual immunotherapy tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma	3	Open	N/A
12/WM/0341	30/11/2014	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardi	10	Open	N/A
12/NW/0694	31/12/2014	A 12-week randomized, open-label, active comparator period followed by a 12-week safety extension period to evaluate the safety and efficacy of Fesoterodine in subjects aged 6 to 16 years and >25 kg with symptoms of detrusor overactivity associated with a	2	Open	N/A
13/EM/0284	29/12/2014	A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum double	10	Open	N/A
13/EE/0241	09/10/2014	Secukinumab In patients with moderate to severe active, chronic plaque psoriasis who have failed on TNFa antaGoNists: A clinical Trial EvalUating Treatment REsults (SIGNATURE)	2	Open	N/A

13/NW/0692	31/03/2016	A multicenter, international, randomized, parallel group, double blind, placebo-controlled Cardiovascular Safety & Renal Microvascular outcome with LINagliptin, 5 mg once daily in patients with type	10	Open	N/A
13/EE/0326	30/06/2015	REVACEPT, AN INHIBITOR OF PLATELET ADHESION IN SYMPTOMATIC CAROTID STENOSIS: A PHASE II, MULTICENTRE; RANDOMISED, DOSE-FINDING, DOUBLE-BLIND AND PLACEBO-CONTROLLED SUPERIORITY STUDY WITH PARALLEL GROUPS	6	Open	N/A
13/EE/0377	31/08/2014	A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids	3	Open	N/A
12/YH/0475	01/09/2014	A PHASE Ib MULTICENTER DOSE-FINDING AND SAFETY STUDY OF GDC-0199 AND OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY OR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA	5	Open	N/A
13/SC/0384	30/03/2015	A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma	2	Open	N/A
13/NI/0148	27/05/2018	A phase II, randomised, doubleblind, placebocontrolled, multicentre trial to assess the oral corticosteroidsparing effect of lebrikizumab in patients with with severe corticosteroiddependant asthma	12	Open	N/A
13/LO/1517	04/05/2015	Phase 3, Randomized, Open Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG4592 in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis	4	Open	N/A

13/SC/0490	31/08/2018	A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma who are on inhaled corticosteroids and second controller medication.	5	Open	N/A
13/SC/0616	29/07/2016	A Phase II, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' investigational vaccine GSK2838504A, when administered intramuscularly according to a 0, 2 month s	10	Open	N/A
14/ES/0001	05/05/2015	Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment with Ertugliflozin (MK-8835/PF-04971729) in Participants with Type 2 Diabetes Mellitus and Established Vascular Disease	7	Open	N/A
13/EM/0460	14/02/2016	A RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL COMPARING CHEMOTHERAPY PLUS TRASTUZUMAB PLUS PERTUZUMAB VERSUS CHEMOTHERAPY PLUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2 POSITIVE PRIMARY BREAST CANCER	7	Open	N/A
14/EM/0101	20/10/2014	An exploratory, 12 week, randomised, partially double-blinded, placebo-controlled, parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed dose combination or tiotropium (both delivered by the R	3	Open	N/A
14/SC/0185	01/06/2015	A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg with Placebo on Glycemic Control in Patients with Type 2 Diabetes on Basal Insulin Glargine (AWARD-9: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 9)	5	Open	N/A

13/WM/0451	22/05/2015	A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in subjects with MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors	3	Open	N/A
14/EE/0102	31/12/2015	A prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing planned electrical cardioversion of nonvalvular atrial	9	Open	N/A
14/EM/0209	29/12/2014	An open label, intra-subject, controlled multi-centre study to assess the concordance (specificity and sensitivity) between Colourstart® Test 73 mcg Cutaneous Patch and Finn Chamber in the detection of para-Phenylenediamine (PPD) allergy in subjects with	30	Open	N/A
14/SC/0065	15/06/2015	A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus	8	Open	N/A
14/LO/0673	28/02/2017	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant	8	Open	N/A
14/YH/0086	11/12/2020	RESPOND: Repositionable Lotus Valve System – Post Market Evaluation of Real World Clinical Outcomes	15	Open	N/A
14/LO/1050	01/06/2016	A Multicenter Phase 3 Randomized Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia.	7	Open	N/A
14/YH/0141	01/10/2018	nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation	25	Open	N/A

14/LO/0818	24/12/2015	A Randomized Open-Label Phase III Trial of MK-3475 versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer	10	Open	N/A
14/LO/0865	01/12/2015	A Phase 2, Multi-Center, Randomized, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy	4	Open	N/A
14/NE/1018	31/07/2016	A randomised, double-blind, chronic dosing (56-week), placebo-controlled, parallel group, multicentre, phase III study to evaluate the efficacy and safety of 2 doses of benralizumab (MEDI-563) in patients with severe to very severe Chronic Obstructive Pul	6	Open	N/A
14/EM/0034	30/07/2015	A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB	3	Open	N/A
14/WM/1055	14/02/2016	A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination	5	Open	N/A
14/EM/1059	15/12/2014	A Phase 3, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	2	Open	N/A
14/EM/0186	01/04/2015	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	2	Open	N/A

14/EM/1068	19/07/2015	MYL-GAI-3001. AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL-GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLANS INSULIN GLARGINE WITH LANTUS® IN TYPE 1 DIABETES MELLITUS PATIENTS.	5	Open	N/A
13/NW/0283	30/06/2015	GLOBAL LEADERS: Comparative effectiveness of 1 month of ticagrelor plus aspirin followed by ticagrelor monotherapy versus a current-day intensive dual antiplatelet therapy in all-comers patients undergoing percutaneous coronary intervention with bivalirud	100	Open	N/A
12/SC/0173	30/04/2014	A Multicentre, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Paediatric Patients with Type 2 Diabetes who have Inadequate Glycaemic Co	2	Suspended	N/A
13/EM/0340	01/09/2014	A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion	1	Suspended	N/A
07/S0501/91	31/12/2009	An open label, single arm, multi centre phase II trial with ofatumumab in patients with relapsed Diffuse Large B Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant	5	Closed - follow-up complete	N
08/H0206/34	31/07/2010	A Multicentre, Double-Blind 3-Arm, Phase 1b/2 Study in Subjects with Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment with Epirubicin Cisplatin and	7	Closed - follow-up complete	N

08/MRE00/93	30/11/2009	A single-arm, international, multi-centre trial investigating the efficacy and safety of atumumab re-treatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia who progressed following response or stable disease after of atum	10	Closed - follow-up complete	N
08//H0703/132	30/09/2011	An open-label, multi-centre, randomised, phase Ib study to investigate the safety and efficacy of RO5072759 given in combination with CHOP or FC chemotherapy in patients with CD20+ relapsed/refractory B-cell follicular non-Hodgkin's lymphoma.	2	Closed - follow-up	Y
09/H0406/5	30/09/2010	A phase IA/II multi-centre open label study of HCD 122 administered once weekly for four weeks in adult patients with advanced non Hodgkins or Hodgkins lymphoma who have progressed after at least two prior therapies	10	Closed - follow-up complete	N
09/H0402/71	30/09/2011	A phase I multicentre, open label, dose escalation study of oral LDE225 in patients with advanced solid tumours.	5	Closed - follow-up	Y
09/H0402/92	31/08/2011	A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer.	10	Closed - follow-up complete	Y
09-WSE04-55	01/06/2012	An open-label, multi centre, three arm randomised, phase III study to investigate the efficacy and safety of R05072759 + chlorambucil (GClb), rituximab and chlorambucil (RCIb) or chlorambucil (Clb) alone in previously untreated CLL patients with co-morbid	5	Closed - follow-up	Y
10/H0402/33	30/03/2012	CAVALIER: Perceval S valve clinical trial for extended CE mark	15	Closed - follow-up	Y

09/H0903/51	31/12/2012	An Extension Treatment Protocol for Subjects who have participated in a Phase 3 study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)	5	Closed - follow-up complete	N
10/MRA00/84	26/07/2013	A phase I, multicenter, open-label dose escalation study of LDK378, administered orally in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase(ALK)	2	Closed - follow-up	Y
10/H0406/90	20/02/2013	A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI-906 plus Erlotinib (Tarceva®), or Erlotinib plus Placebo in Patients with Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC	3	Closed - follow-up complete	Y
10/H0806/106	01/10/2012	An open Phase I Study of immunization with the recNY-ESO-1 + AS15 Antigen-Specific Cancer Immunotherapeutic in patients with NY-ESO-1-positive unresectable and progressive metastatic cutaneous melanoma	4	Closed - follow-up complete	N
08/H0502/133	31/03/2012	BH21260- A randomised, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment wit	10	Closed - follow-up	N
11/EM/0225	30/06/2014	A PHASE III, MULTICENTER, RANDOMISED TRIAL COMPARING THE EFFICACY OF GA101 IN COMBINATION WITH CHOP (G-CHOP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)	5	Closed - follow-up	N
11/NI/0147	30/04/2012	Assessment of the 23mm St Jude Medical Portico transcatheter Aortic Valve Implant (TAVI) and the SJM TAVI Transfemoral Delivery System (Portico 23-TF EU)	12	Open	Y

11/LO/1271	01/07/2012	Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer - Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients with NSCLC-C	14	Closed - follow-up	N
11/LO/1272	01/07/2012	Anamorelin HCl in the Treatment of NonSmall Cell Lung Cancer Cachexia (NSCLCC): An Extension Study	14	Closed - follow-up complete	N
11/LO/0054	01/12/2012	NGR015: Randomized double-blind phase III study of NGR-hTNF plus best investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM)	15	Closed - follow-up	N
11/SC/0499	30/11/2012	A UK openlabel, multicentre, phase II exploratory study of INC424 for patients with primary myelofibrosis (PMF) or post polycythaemia myelofibrosis (PPV MF) or postessential thrombocythaemia myelofibrosis (PETMF)	3	Closed - follow-up	Y
11/AL/0393	01/06/2013	A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Stage IIIb or IV Non-Small-Cell Lung Cancer	20	Closed - follow-up complete	N
12/LO/0806	30/04/2013	A Multicenter, Single arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients with Metastatic Colorectal Cancer (mCRC) Previously Treated with an Oxaliplatin-Containing Regimen	5	Closed - follow-up	Y
12-LO-0928	28/02/2013	MASERATI 100 A prospective, Multicenter, postmarket, single Arm observational study to collect clinical outcome data on the use of Permacol™ Collagen Paste in the treatment of anorectal fistulas	10	Closed - Follow up	Y

12/SC/0139	30/11/2013	A Phase III Prospective, Two-cohort, Non-randomized, Multi-centre, Multi-national, Open Label Study to Assess the Safety of Assisted- and Self-administered Subcutaneous Trastuzumab as Adjuvant Therapy in Patients with Operable HER2-positive Early Breast C	10	Closed - follow-up	N
12/EM/0204	15/07/2015	An open-label, multi-centre, non-randomised phase I dose-escalation study to investigate the safety and tolerability of ONO-4059 given as monotherapy in patients with relapsed/refractory Non-Hodgkin's lymphoma (NHL) and relapsed/refractory chronic lymphoc	7	Open	N/A
12/NW/0242	01/03/2013	An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy	15	Closed - follow-up	N
12/NE/0009	01/09/2015	A Phase II, Double-Blind, Placebo Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab with and without GDC-0941 in patients with Previously Untreated Advanced or Recurrent Non-Sm	9	Open	N/A
12/LO/1313	31/12/2013	ROX CONTROL HTN Study: A Prospective, Randomized, Open-Label, Multicenter Study to Evaluate the ROX Coupler in Patients with Resistant Hypertension	20	Closed - Follow up	N
12/EM/0206	30/09/2013	An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody – maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refractory CD19+ diffuse large B cell lymphoma	2	Closed - Follow-up	Y
12/NE/0333	01/11/2013	A multicentre, open label, early stopping design, proof of concept study with tasquinimod in treating patients with advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas.	10	Closed - follow-up	N

13/ES/0088	30/06/2015	A Multicentre, double blind, randomized, parallel group, placebo-controlled study to evaluate the effects of intravenous serelaxin infusion on micro - and macro-vascular function in subjects with coronary artery disease.	30	Open	N/A
13/LO/1766	31/10/2015	A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indicati	3	Suspended	N
13/EM/0476	17/11/2017	ABSORB UK Registry A postmarket registry of patients with de novo lesions in previously untreated vessels treated with Absorb BVS	30	Open	N/A
13/SS/0072	31/10/2013	Patient-reported outcomes of Brimonidine Tartrate 0.5% gel for treatment of severe facial erythema of rosacea	4	Closed - in follow up	N